10-Q: BioCardia Faces Liquidity Crisis Amid Rising R&D Costs

BioCardia, Inc. reported significant net losses and a critical cash shortage, raising substantial doubt about its ability to continue operations beyond October 2025, despite ongoing clinical trial progress.

Summary

• BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases.
• The company reported a net loss of $2.049 million for the three months ended June 30, 2025, and $4.761 million for the six months ended June 30, 2025.
• Research and development expenses increased to $1.368 million for Q2 2025 (up from $800,000 in Q2 2024) and $2.898 million for the six months ended June 30, 2025 (up from $2.041 million in the prior year period).
• Selling, general and administrative expenses decreased to $683,000 for Q2 2025 (down from $852,000 in Q2 2024).
• Cash and cash equivalents stood at $980,000 as of June 30, 2025, down from $2.371 million at December 31, 2024.
• The accumulated deficit reached approximately $164.9 million as of June 30, 2025.
• Management believes current cash and cash equivalents are not sufficient to fund planned expenditures beyond October 2025.
• The company is not in compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million, with stockholders' equity at $(1.886) million as of June 30, 2025, and was $837,000 as of December 31, 2024.
• Multiple equity financings were completed, including private placements in April and June 2025, and ongoing At-the-Market (ATM) offerings.
• Clinical trials for CardiAMP autologous cell therapy (CardiAMP HF, CardiAMP HF II, CardiAMP CMI) and CardiALLO allogeneic MSC therapy are progressing.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative due to severe liquidity issues, a going concern warning, Nasdaq non-compliance, and increasing losses with no revenue. While clinical progress is noted, the immediate financial viability overshadows these developments, indicating high risk and an urgent need for capital.

Positives

• CardiAMP Cell Therapy for ischemic heart failure received FDA Breakthrough designation.
• Two-year results from the CardiAMP HF Trial showed reduction in all-cause death, reduced major adverse cardiac events, and improved quality of life, with a statistically significant composite endpoint in patients with elevated NTproBNP.
• Patient randomization has commenced in the CardiAMP HF II Phase 3 trial, with four centers actively enrolling.
• Medicare reimbursement code C9782 ($17,500) helps offset costs for CardiAMP HF and CMI studies.
• Open-label roll-in cohort results for CardiAMP Cell Therapy in chronic myocardial ischemia showed an average 107-second increase in exercise tolerance and an 82% average reduction in angina episodes at six months.
• The low-dose cohort of the CardiALLO allogeneic MSC Phase 1/2 trial for HFrEF has been completed with no treatment-emergent adverse events, arrhythmias, rejection, or allergic response.
• The Data Safety Monitoring Board recommended proceeding with the CardiALLO study design in April 2025.
• The Helix transendocardial biotherapeutic delivery system has a high safety standard with over 4,000 intramyocardial deliveries.
• FDA market clearance was received for the Morph DNA steerable introducer (AVANCE) for transseptal cardiac procedures.

Negatives

• The company has incurred net losses and negative cash flows from operations since inception, with an accumulated deficit of $164.9 million as of June 30, 2025.
• Cash and cash equivalents of $980,000 as of June 30, 2025, are not sufficient to fund planned expenditures beyond October 2025.
• Net loss increased to $4.761 million for the six months ended June 30, 2025, compared to $3.913 million for the same period in 2024.
• Operating loss increased to $4.777 million for the six months ended June 30, 2025, compared to $3.924 million for the same period in 2024.
• Revenue was $0 for the three and six months ended June 30, 2025, a significant decrease from $3,000 and $58,000 in the prior year periods, respectively.
• Cash used in operating activities increased to $3.267 million for the six months ended June 30, 2025, compared to $2.842 million for the same period in 2024.
• The company is not in compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million, having a deficit of $1.886 million as of June 30, 2025.
• Future equity offerings to raise capital may result in significant dilution for existing common stockholders.

Risks

• Substantial doubt exists about the ability to continue as a going concern beyond October 2025 due to insufficient cash and ongoing operating losses.
• Failure to raise additional capital could lead to reduced operating expenses, delayed or reduced product development, relinquishing rights to technologies, or cessation of operations.
• The company is not in compliance with Nasdaq's minimum stockholders' equity requirement, risking delisting of common stock if compliance is not regained by September 29, 2025.
• Delisting from Nasdaq could decrease trading volume and share price, make it harder to raise capital, and potentially trigger defaults under financing arrangements.
• Future equity offerings will likely result in significant dilution for existing stockholders.
• The amount and timing of collaboration revenues are largely dependent on partners' development activities and may be inconsistent.
• The company's ability to generate meaningful revenue from biotherapeutic delivery partnering or sales of approved therapies is uncertain.
• The realization of deferred tax assets is uncertain, leading to a full valuation allowance.

Future Outlook

The company expects operating losses and negative cash flows to continue for at least the next several years as it advances clinical trials and development activities. Additional funding will be required beyond October 2025 to continue operations and therapeutic candidate development. The company plans to raise additional capital through debt, equity, non-dilutive collaborations, or licensing arrangements. It anticipates submitting CardiAMP HF data to the FDA in Q4 2025 to discuss approvability and expects an in-person consultation with Japan's PMDA in Q4 2025 regarding CardiAMP system approval for market entry in Japan. Phase 2 development for CardiALLO is anticipated to advance in the US and Japan, with potential for conditional approval in Japan after completion of the Phase 2 study. The company intends to submit a DeNovo 510(k) application to the FDA for the Helix Transendocardial Delivery System.

Management Comments

• Management believes current cash and cash equivalents are not sufficient to fund planned expenditures and meet obligations beyond October 2025.
• Management plans to raise additional capital, potentially including debt and equity arrangements, to finance future operations.
• Management believes their plan to raise additional funds will alleviate the conditions that raise substantial doubt, but these plans are not entirely within their control and cannot be assessed as being probable of occurring.
• The company intends to prepare the primary results of the CardiAMP CMI roll-in cohort for publication and presentation.
• The Data Safety Monitoring Board recommended that the CardiALLO study proceed as designed in April 2025 based on 30-day data safety assessment.
• The company intends to fund CardiALLO development through non-dilutive grants and partnering.
• The company is actively transitioning all procedures using the Helix transendocardial delivery system to the new FDA cleared Morph DNA platform.
• The company believes the Morph DNA platform presents significant advantages for procedures in the left ventricle of the heart, such as cell and gene therapy and ablation of ventricular tachyarrhythmia.

Industry Context

BioCardia operates in the highly capital-intensive clinical-stage biotechnology sector, specifically focusing on cell and gene therapies for cardiovascular and pulmonary diseases. The development of novel therapeutics in this space requires significant and sustained investment in research, clinical trials, and regulatory processes. The company's strategy of developing both autologous and allogeneic cell therapies, alongside proprietary delivery systems like Helix and Morph DNA, aligns with broader industry trends towards personalized medicine and advanced delivery technologies. However, the industry is characterized by high failure rates and long development timelines, making consistent funding a critical challenge, especially for companies without significant commercial revenue. The pursuit of FDA Breakthrough designation and engagement with regulatory bodies like Japan's PMDA reflects the global nature of drug development and the potential for accelerated pathways for promising therapies.

Comparison to Industry Standards

• NA The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks. The focus is on internal clinical trial progress and financial standing.

Legal Proceedings

• Management is not aware of any current legal or administrative proceedings that are likely to have an adverse effect on the business, financial position, results of operations, or cash flows.

Related Party Transactions

• Certain of the company's directors and executive officers purchased an aggregate of 211,000 shares of Common Stock and accompanying Common Warrants in the September 2024 Registered Offering.
• Certain members of the board of directors and executive officers participated in the April 2025 and June 2025 private placements.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing and future equity capital raises.
• Shareholders face potential loss of investment if the company cannot secure additional funding and is forced to cease operations or liquidate assets.
• Shareholders face the risk of delisting from Nasdaq, which could negatively impact share price and liquidity.
• Employees may face uncertainty regarding job security due to the company's going concern issues and potential need to reduce operating expenses.
• Creditors may face increased risk due to the company's precarious financial position and substantial doubt about its ability to continue as a going concern.
• Customers (if any, though revenue is minimal) and suppliers may face uncertainty regarding the company's long-term viability and ability to fulfill obligations.

Next Steps

• Raise additional capital through debt, equity, non-dilutive collaborations, or licensing arrangements.
• Complete submission of CardiAMP HF data and request a meeting with the FDA in Q4 2025 to discuss approvability.
• Anticipate an in-person consultation with Japan's PMDA in Q4 2025 regarding CardiAMP system approval for market entry in Japan.
• Continue patient randomization and onboarding additional centers for the CardiAMP HF II Phase 3 trial.
• Prepare primary results of the CardiAMP CMI roll-in cohort for publication and presentation.
• Advance Phase 2 development for CardiALLO in both the United States and Japan, with enrollment anticipated in approximately one year.
• Potentially pursue conditional approval for CardiALLO in Japan after completion of the Phase 2 study, followed by a post-marketing study.
• Submit a DeNovo 510(k) application to the FDA for the Helix Transendocardial Delivery System.
• Regain compliance with Nasdaq's minimum stockholders' equity requirement by September 29, 2025.

Key Dates

Recommendation

The company faces an immediate and severe liquidity crisis, with cash sufficient only until October 2025. The explicit 'going concern' warning, coupled with increasing net losses, zero revenue, and non-compliance with Nasdaq listing requirements, indicates extreme financial distress. While clinical programs show some promise, the company's ability to fund these programs and continue operations is highly uncertain. The reliance on highly dilutive equity raises to survive, and the risk of delisting, make the stock a high-risk investment with significant downside potential in the near term. A seasoned investor would recognize the imminent risk of capital loss and advise divesting.

Keywords

Cell Therapy, Cardiovascular Disease, Heart Failure, Refractory Angina, Ischemic Heart Disease, Clinical Trials, Biotechnology, Medical Devices, SEC Filing, 10-Q, Going Concern, Nasdaq Delisting, Capital Raise